CAR-T for hard-to-treat lupus: pooled data on 243 patients show sharp drop in disease activity

CAR T-cell therapy, first developed for blood cancers, is increasingly being tested in systemic lupus erythematosus (SLE), an autoimmune disease with no cure. At the American College of Rheumatology’s ACR Convergence 2026 meeting, researchers from Hospital for Special Surgery (HSS) in New York presented a pooled analysis of the evidence so far.

What they did

The team systematically reviewed 31 studies covering 243 people with lupus who had already tried at least two immunosuppressants, with outcomes followed over up to two years. Most patients received personalised CD19-targeted CAR-T made from their own immune cells, which aim to wipe out the B cells driving the autoimmune attack.

Results

• Mean SLEDAI disease-activity score fell from 13.0 at baseline to 2.2 six months after treatment.
• 64% had cytokine release syndrome (CRS), mostly mild: 61% of all patients had grade 1–2 CRS.
• 5% had the neurological complication ICANS, 5% had severe (grade 3–4) infections, and 6% had blood-count toxicity lasting more than 28 days.

Senior author Anca Askanase said the therapy could shift treatment goals “from disease control toward sustained remission” and potentially a cure. Other ACR abstracts this week reported early results of newer designs, including an off-the-shelf (allogeneic) CAR-T targeting both CD19 and BCMA.

Limitations

This is a meeting presentation of a pooled review, not a peer-reviewed paper or a randomised trial. As HSS itself notes, the individual studies are small, mostly uncontrolled and differ in products and follow-up; patients were highly selected; and long-term durability and safety are not yet known. Larger prospective studies are needed.